Interventional Cardiology

Contact Information

Boswell Building
Room A260, (2nd floor)
300 Pasteur Drive
Stanford, CA 94305
Driving directions

(650) 725-2621

(650) 725-6766

Clinic Hours
Monday - Friday
8:30am - 5:30pm

Interventional cardiology refers to diagnostics and non-surgical treatments of the heart. Cardiac interventions are used to diagnosis and treat coronary artery disease, valvular heart disease and congenital heart disease.

Stanford interventional cardiology is a world leader in percutaneous coronary revascularization, which re-establishes blood flow to the heart when its vessels have been damaged or blocked. We perform approximately 1,000 interventions per year and offer the latest breakthroughs in the treatment of coronary artery disease and valvular heart disease.

In addition, Stanford Cardiovascular Health offers state-of-the-art cardiac catheterization using low-radiation, high-resolution digital equipment that maximizes both patient safety and image quality.

Stanford's three cath labs perform more than 4,000 procedures annually, roughly half on an outpatient basis. Our fourth and fifth laboratories are dedicated to cardiac electrophysiology.

Balloon Aortic Valvuloplasty (BAV) is a method used to temporarily relieve aortic stenosis (narrowing of the aortic valve) by inflating a balloon within the narrowed valve. Because the benefit of this procedure is variable and may only last weeks to months, it is performed only in patients who are not immediate candidates for traditional surgical aortic valve replacement or transcatheter aortic valve replacement.

Transcatheter Aortic Valve Implantation (TAVI*) is an investigational (non-FDA approved), less invasive, innovative catheter based therapy to relieve aortic stenosis; it combines the skills of Stanford’s cardiologists, cardiovascular surgeons, and cardiovascular anesthesiologists. Outside the U.S., TAVI is assuming a major role in the management of symptomatic patients with severe aortic stenosis who are unfit to undergo open surgical AVR or who are very high risk for AVR. Stanford has been enrolling in TAVI clinical trials since 2008.


Stanford Medicine Resources:

Footer Links: